Scarica l'app Stockscreener
83.08
0.95%
0.78
Dopo l'orario di chiusura:
83.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$82.30
Aprire:
$82
Volume 24 ore:
507.52K
Relative Volume:
0.58
Capitalizzazione di mercato:
$5.19B
Reddito:
$209.18M
Utile/perdita netta:
$52.04M
Rapporto P/E:
116.60
EPS:
0.7125
Flusso di cassa netto:
$37.10M
1 W Prestazione:
-0.41%
1M Prestazione:
-6.42%
6M Prestazione:
+50.64%
1 anno Prestazione:
+116.58%
Intervallo 1D:
$82.00
$83.87
Intervallo di 1 settimana:
$80.27
$85.50
Portata 52W:
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
83.08 | 5.15B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-12 | Iniziato | Leerink Partners | Outperform |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $338,416.92 in Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 13,151 Shares of Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares - MarketBeat
Protagonist Therapeutics CEO Patel sells $4m in shares By Investing.com - Investing.com India
VIX Spike: Can Protagonist Therapeutics Inc weather a recessionStop Loss & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Technical Reactions to PTGX Trends in Macro Strategies - Stock Traders Daily
Have Insiders Sold Protagonist Therapeutics Shares Recently? - Sahm
Earnings Risk: Will Protagonist Therapeutics Inc benefit from AI trendsAnalyst Downgrade & Daily Market Momentum Tracking - baoquankhu1.vn
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - citizen-times.com
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - southbendtribune.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
US Market Wrap: Is Protagonist Therapeutics Inc trading at a discount2025 Bull vs Bear & Free Community Consensus Stock Picks - baoquankhu1.vn
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - FinancialContent
Earnings Report: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Aug Macro: Can Protagonist Therapeutics Inc expand into new marketsM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Aug Action: Is BIOX a strong growth stockWeekly Trend Report & Verified Stock Trade Ideas - baoquankhu1.vn
Risk On: Should I add GPUS stock to my portfolio2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - news-journalonline.com
With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter - Citeline News & Insights
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Market Fear: Can Protagonist Therapeutics Inc sustain its profitabilityPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trading the Move, Not the Narrative: (PTGX) Edition - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途资讯
Day Trade: Can Protagonist Therapeutics Inc expand into new marketsJuly 2025 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Fundamentals Check: Is Protagonist Therapeutics Inc stock a falling knife or bargain buyShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Protagonist Therapeutics, Inc Updates on Clinical Developments and Collaborations - TradingView — Track All Markets
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - greenvilleonline.com
Is Protagonist Therapeutics Inc. stock overvalued by current metricsWeekly Risk Report & Verified Momentum Watchlists - ulpravda.ru
Is Protagonist Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Reliable Entry Point Alerts - Улправда
Protagonist Therapeutics, Inc.Common Stock (NQ: PTGX - FinancialContent
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessWatch List & AI Driven Stock Reports - Улправда
History Review: How Protagonist Therapeutics Inc. stock benefits from strong dollarJuly 2025 Snapshot & Daily Volume Surge Signals - Улправда
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Accurate Intraday Trade Tips - Улправда
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 14.44% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):